Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Single vs. Multiple Agents in 2L Therapy for CLL

SOHO Brazil 2024

J. Burger

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

Venetoclax vs. BTKis in CLL Treatment

City of Hope

A. Danilov

Impact of Ibrutinib Dose Modifications in CLL

Ruemu Birhiray

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs.…

Constantine Tam

Guidelines for Dose Reduction of Ibrutinib in CLL

Matthew McKinney

ASCO® 2024 Insights: "CAPTIVATE Study - 5.5-Year Follow-Up Outcomes …

2024 ASCO® Annual Meeting Insights Hub

R. Jacobs

Current Options for Finite-Duration Therapy With BTKis in CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Ibrahim